Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
The American Urological Association 2011 Conference takes place on May 14-19 and The Doctor’s Channel will be providing daily highlights coverage. Check back daily for highlights for highlights…
NEW YORK (Reuters Health) – Men who receive radiation treatment for prostate cancer are at greater risk of hip fracture, a new study in the March 16 issue…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses the longstanding treatment options used in addition to chemotherapy, including antiadrogens and CYP inhibitors.…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses Androgen Deprivation Therapy. Androgen Deprivation Therapy is the gold standard for men with metastatic…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses her experience with men who have been treated aggressively for low grade, low volume…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses new research led by the Eastern Cooperative Oncology group looking at a RCT of…
The American Association of Clinical Endocrinologists 2011 Conference takes place on April 13-17 and The Doctor’s Channel will be providing daily highlights coverage. Check back daily for highlights…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses how radical prostatectomy can provide a definitive cure in many cases of prostate cancer.…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses how prostate cancer requires an integrated multidisciplinary approach. Related ReadingEnhancing prostate cancer care through…
NEW YORK (Reuters Health) – An updated review of medications available for treating type 2 diabetes concludes that metformin continues to have the best benefit-to-harm profile, according to…
